Drugs / Xigduo
last change Jun 2025 re-read 2 minutes ago

Xigduo

Developed for
type 2 diabetes mellitus
Investigated by
AstraZeneca

Regulatory milestones approvals, filings & regulatory actions · 1 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Approved EU (EMA) Xigduo 2014-01-16 europa.eu

Trials 1 · a red edge is where a trial was stopped

today
EU approved 2014
NCT06327815 · Ph 4
20142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 4 NCT06327815 Mar 2024 → Jun 2025 type 2 diabetes mellitus AstraZeneca Completed No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Xigduo ClinicalTrials.gov intervention name — accepted as the source's own label NCT06327815